# Practical issues in health services research in Switzerland: Experience with an end-of-life study in cancer patients.



Gruppo Svizzero di Ricerca Clinica sul Cancro

Klazien Matter-Walstra <sup>1,2)</sup>, Rita Achermann <sup>3)</sup>, Andrea Bordoni <sup>4)</sup>, Silvia Dehler <sup>5)</sup>, Gernot Jundt <sup>6)</sup>, Isabelle Konzelmann <sup>7)</sup>, Matthias Schwenkglenks <sup>1)</sup>, Bernhard C. Pestalozzi <sup>8)</sup> on behalf of the Swiss Group for Clinical Cancer Research (SAKK)

1) Institute of Pharmaceutical Medicine (ECPM), University Basel, 2) Swiss Group for Clinical Cancer Research Coordination Center (SAKK), Bern, 3) formerly Helsana, 4) Cancer Registry Ticino, 5) Cancer Registry Zürich and Zug, University Hospital Zürich, 6) Cancer Registry Baselstadt and Baselland, University Hospital Basel, 7) Cancer Registry Valais, Sion, 8) President network outcomes research, SAKK / Department Oncology, University Hospital Zürich

# Background

Cancer registries, health insurance companies and administrative bodies can contribute important data for health services research (HSR). However, using and combining data from different sources may be challenging.

## Methods

We describe the process of activating an end-of-life patterns of care study in Swiss cancer patients deceased in 2006-2008 that were enrolled with one health insurance company (Helsana)

To identify cancer patients in the insurance data base, insurance and cancer registry data had to be combined.


In order to complement insurance-based inpatient information, medical records of hospitalized patients had to be reviewed for in-stay use of resources.

These data collection and linkage procedures gave rise to several complicated administrative issues that had to be resolved.

#### Results


- In a first step the ethics committees and an advisory body of the Swiss Federal Office of Public Health had to decide on **responsibility for granting permission** to obtain and combine data. This process lasted almost one year. The time line of these procedures is shown in Table 1.
- The identification of eligible patients using cancer registry data from four cantons worked well even with diverse database structures.
- Retrieving details on **in-stay resource use** not available from the insurance database required additional approvals. We had to contact 49 hospitals and perform an extensive medical chart review. This applied to 68% of 3873 eligible patients; 94.5% of relevant hospitalization episodes were evaluated in 37 hospitals. The results are shown in Figure 1.

# Table 1: Time-line of the End-of-Life study activation



## **Acknowledgements:**


We would like to thank all persons involved for their time, co-operation and encouragement.



Cancer related death information is only systematically available for those patients who were subject to a medical chart review.

#### Discussion

### Time intensive and complicating issues for HTA studies



# Conclusion

HSR studies in Switzerland with large datasets are possible but need perseverance and may involve laborintensive processes to complement lacking information.

As this type of study will become more common, simplifying and standardizing the process of obtaining permissions and data collection is necessary.